Pharming Technologies B.V.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-19
ACTIVE TRIALS5
PHASE 3 / 2-32
RECRUITING2
READOUTS ≤12 MONTHS2
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Leniolisib NCT05438407 |
P3 | Active, not recruiting | APDS | 15 | 2026-11-30 (+30 mo) |
| FALCON NCT05650229 |
P2 | Recruiting | Primary Mitochondrial Disease | 180 | 2027-10 (+24 mo) |
| Leniolisib NCT05693129 |
P3 | Active, not recruiting | APDS | 16 | 2028-07-09 (+42 mo) |
| Falcon-OLE NCT07514338 |
P2 | Recruiting | Mitochondrial Diseases | 140 | 2029-03-31 |
| Leniolisib NCT06990529 |
P2 | Active, not recruiting | PIDs Linked to PI3K | 12 | 2029-08-12 (+11 mo) |